An emerging research trajectory is converging on ultraweak photon emissions (UPE) as a candidate biophotonic signal of brain function, giving rise to a nascent modality termed "photoencephalography." This trend reframes the brain not merely as an electrochemical organ but as a source of spontaneous and stimulus-evoked biophotons—generated even in cells at rest and modulated by neurotransmitter activity, biophysical stimuli, tasks, and cognitive states. The central scientific ambition is to establish UPE as an optical readout of functional brain states, paralleling EEG's readout of electrical activity, with proposed applications spanning oxidative stress detection, neurodegeneration prediction, and indexing of "physiological coherence" as a marker of synchronized biological processes. Mechanistically, UPE is hypothesized to arise from reactive oxygen species and metabolic processes and to potentially subserve a novel channel of cell-to-cell communication among neural cells, positioning biophoton emission as both a passive biomarker and an active signaling modality.
Methodologically, the field is building out standardized infrastructure: protocols for measurement and analysis of photoencephalographic signals, photomultiplier tubes and modern photodetectors for signal capture in dark environments, and simultaneous EEG recording (including alpha-wave monitoring during meditation/breathwork paradigms) to cross-validate photonic signals against established electrophysiological correlates. Data processing pipelines are being developed to support signal interpretation, while spectral and entropic properties of UPE are proposed as features that distinguish genuine neural emissions from background light contamination. This reflects a broader trend of multi-modal biomarker fusion, where photonic, electrical, and biochemical signals are triangulated to characterize brain states with greater confidence than any single modality alone.
However, this trajectory is tempered by significant unresolved skepticism about signal provenance and instrumentation adequacy. A critical counter-narrative within the same literature cluster identifies the scalp—not the brain—as the likely dominant source of detected extracranial photon emission, since skull and scalp tissue strongly attenuate photons below 600 nm, precisely the range where common photomultiplier tubes retain sensitivity. This creates a fundamental measurement paradox: the instruments most commonly used may be spectrally blind to the deeper-tissue, longer-wavelength photons that would need to penetrate the skull to reflect true neural (rather than dermal/vascular) activity. This tension—between an aspirational biomarker platform and hard biophysical constraints on signal transmission and detection—defines the current maturation stage of the field, suggesting that near-term progress will depend on resolving source localization, improving photodetector spectral range, and rigorously validating UPE-brain rhythm correlations before photoencephalography can be considered a reliable clinical neuroimaging tool.